United Therapeutics Corporation UTHR
588.61 USD +6.15 (+1.06%)
At closeNov 10, 2026, 6:30 PM EST
588.61 0.00 0.00%
After hours · Nov 10, 6:30 PM ET
577.26 Day range 593.10
453.93 52-week range 608.49
- YTD
- +20.80%
- 1 year
- +29.67%
News
gurufocus.com United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update d
247wallst.com Buy, Sell, or Hold? Monday’s Top Upgrades and Downgrades: Advanced Micro Devices, Airbnb, DraftKings, L3 Harris Technologies, Molson-Coors, Nvidia, Take-Two Interactive, Uber Technologies, and More Nvidia just lost a vote of confidence while AMD earned a $600 target, and Wall Street's chip debate is splitting wide open. Add a Fed rate hike looming and a flurry of fresh Citigroup calls, and…
businesswire.com United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will…
benzinga.com HC Wainwright & Co. Assumes United Therapeutics at Buy, Announces Price Target of $660 HC Wainwright & Co. analyst Matthew Caufield assumes United Therapeutics (NASDAQ:UTHR) with a Buy rating and announces Price Target of $660.
benzinga.com TD Cowen Maintains Buy on United Therapeutics, Raises Price Target to $700 TD Cowen analyst Joseph Thome maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $675 to $700.- benzinga.com RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $725 RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $697 to $725.
benzinga.com Wells Fargo Maintains Overweight on United Therapeutics, Raises Price Target to $703 Wells Fargo analyst Benjamin Burnett maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $700 to $703.
marketbeat.com What United Therapeutics (UTHR) Said on Its Q3 Earnings Call United Therapeutics NASDAQ: UTHR reported record third-quarter 2026 revenue of $833 million, driven in part by record Tyvaso sales of $504 million, while pushing back a planned regulatory submission…
seekingalpha.com United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript- benzinga.com BTIG Maintains Buy on United Therapeutics, Raises Price Target to $768 BTIG analyst Julian Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $728 to $768.
zacks.com United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare…
zacks.com United Therapeutics (UTHR) Q3 Earnings Miss Estimates United Therapeutics (UTHR) came out with quarterly earnings of $5.71 per share, missing the Zacks Consensus Estimate of $5.85 per share. This compares to earnings of $7.16 per share a year ago.- benzinga.com United Therapeutics Amends Agreement With Arena Pharmaceuticals, Pfizer Subsidiary, Eliminating All Royalty Obligations Under Its Exclusive License Agreement Related to Ralinepag for an Upfront Payment of $525M This transaction demonstrates our confidence in the revenue opportunity for oral ralinepag, which has a pending new drug application under review by the FDA for pulmonary arterial hypertension, as…
businesswire.com United Therapeutics Announces Buydown of Ralinepag Royalty SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that it has entered into an amendment…
businesswire.com United Therapeutics Corporation Reports Third Quarter 2026 Financial Results SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter…
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
benzinga.com SpaceX Launch Customer Varda Says a Single Flight Could Help Make Medicine for Millions Varda says one SpaceX flight could produce drug crystals capable of supporting medicine for millions of patients.
zacks.com SGIOY vs. UTHR: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and United Therapeutics (UTHR).
benzinga.com JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695 JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $710 to $695.
zacks.com Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com $100 Invested In United Therapeutics 15 Years Ago Would Be Worth This Much Today United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 15 years by 6.41% on an annualized basis producing an average annual return of 19.23%. Currently, United Therapeutics has a…
businesswire.com United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug…
defenseworld.net United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Friday, October 23rd. The shares were sold at an average…
benzinga.com RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697 RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $708 to $697.
businesswire.com United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of…
businesswire.com United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a…
benzinga.com United Therapeutics Opens Third Designated Pathogen-Free Facility, The Dr. Bartley P. Griffith And Dr. Robert A. Montgomery Xenograft Production Facility, In Houston, Texas Named for Dr. Bartley P. Griffith and Dr. Robert A. Montgomery, pioneers in xenotransplantation, the biosecure facility is purpose-built to manufacture United Therapeutics’ xenokidneys and xenohearts…
businesswire.com United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated…
defenseworld.net United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction on Friday, October 16th. The shares were sold at an…
benzinga.com Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 5 years by 11.98% on an annualized basis producing an average annual return of 23.16%. Currently, United Therapeutics has a…- benzinga.com Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725 Leerink Partners analyst Roanna Ruiz maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $685 to $725.
- benzinga.com The FDA Clears United Therapeutics' Investigational New Drug Application To Proceed With SUMMIT Trial Of Treprostinil Soft Mist Inhaler In Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company’s…
businesswire.com United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug…
defenseworld.net United Therapeutics (NASDAQ:UTHR) CEO Sells $5,129,905.00 in Stock United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction dated Wednesday, October 14th. The shares were sold at…
benzinga.com Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain Even as September Inflation Report Comes In Hotter Than Expected— ASML, AZZ, GME in Focus (UPDATED) U.S. stock futures were higher on Wednesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Tuesday's lower close.
benzinga.com Liquidia Settles Bitter Fight With United Therapeutics Liquidia (LQDA) stock jumped 40% after settling all lawsuit battles with United Therapeutics for $380.7M. YUTREPIA PAH sales continue.
benzinga.com Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket Enovix jumps 6.8% after securing a 100,000-unit battery order from a multinational drone maker, with deliveries planned for H1 2027.
benzinga.com Liquidia Corporation Stock Is Trending In After-Hours Following United Therapeutics Settlement: What You Should Know Liquidia shares surged 42.48% in after-hours trading after settling all pending litigation with United Therapeutics over YUTREPIA patents.- benzinga.com Liquidia Will Continue To Advance YUTREPIA And L606 Clinical Programs As Previously Outlined; Liquidia Has Submitted A Supplement To Remove The PH-ILD Indication From YUTREPIA’ ’s Label And No Longer Promotes It For PH-ILD The settlement follows the September 30, 2026, ruling by the U.S. District Court for the District of Delaware (the Court) that claims 1 and 14 of U.S. Patent No. 11,826,327 (the ’327 patent) are…
- benzinga.com Liquidia Enters Into A Global Settlement Agreement With United Therapeutics That Resolves All Pending Litigation Between The Companies; Settlement Fully Resolves Six Ongoing Lawsuits Between Liquidia And United Therapeutics; Liquidia To Pay Net $380.70M In Installments In 2026 And 2027; Liquidia Will Make A Net Payment To UTHR Of $175M Within 30 Business Days Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced…
- benzinga.com RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $708 RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $677 to $708.
- benzinga.com Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $566 Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Weight and raises the price target from $515 to $566.
benzinga.com This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Analysts upgraded BJRI, UTHR, OXY, BP and REGN, raising ratings and/or price targets.- benzinga.com United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia Shares of United Therapeutics are rising Thursday following a federal court victory in its patent litigation against competitor Liquidia.
benzinga.com Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures were mixed as Progress Software fell after results; Corteva, NFT, Vivakor and other stocks also dropped in premarket trading.- benzinga.com BTIG Upgrades United Therapeutics to Buy, Announces $728 Price Target BTIG analyst Julian Harrison upgrades United Therapeutics (NASDAQ:UTHR) from Neutral to Buy and announces $728 price target.
- benzinga.com Reported Earlier, United Therapeutics Prevails In Delaware Court Ruling Finding Liquidia Infringes Two Claims Of Patent On Inhaled Treprostinil For PH-ILD Via Yutrepia Marketing As a result of the Court’s decision, United Therapeutics believes that it is entitled to an order instructing the U.S. Food and Drug Administration (FDA) to withdraw approval of Liquidia’s new drug…
benzinga.com Why is Liquidia (LQDA) Stock Trending After Hours? Liquidia Corp. shares gained 0.13% after hours after closing 57.19% lower following an adverse patent ruling.
benzinga.com Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today Nasdaq 100 gains as softer PCE inflation cools Fed rate-hike bets, with oil above $91 and Micron earnings due after the bell Wednesday.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…